High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms

2003 ◽  
Vol 38 (12) ◽  
pp. 1144-1149 ◽  
Author(s):  
Nobutsugu Abe ◽  
Takashi Watanabe ◽  
Yumi Izumisato ◽  
Yutaka Suzuki ◽  
Tadahiko Masaki ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Neoplasms ◽  
Intrahepatic Cholangiocarcinoma ◽  
High Mobility ◽  
High Mobility Group ◽  
Metastatic Adenocarcinoma ◽  
Potential Use

Hepatitis B virus X protein stimulates high mobility group box 1 secretion and enhances hepatocellular carcinoma metastasis

2017 ◽  
Vol 394 ◽  
pp. 22-32 ◽  
Author(s):  
Shuzhen Chen ◽  
Zihui Dong ◽  
Pinghua Yang ◽  
Xianming Wang ◽  
Guangzhi Jin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
High Mobility ◽  
High Mobility Group ◽  
X Protein ◽  
B Virus ◽  
Carcinoma Metastasis

scholarly journals microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA

2019 ◽  
Vol Volume 11 ◽  
pp. 5821-5834 ◽  
Author(s):  
Zhennan Yun ◽  
Fanqi Meng ◽  
Peiqiang Jiang ◽  
Meng Yue ◽  
Shiquan Li
Keyword(s):  
Hepatocellular Carcinoma ◽  
High Mobility ◽  
High Mobility Group

Role of High Mobility Group Box1 in Pathogenesis of Hepatitis C Virus induced Hepatocellular Carcinoma

2020 ◽  
Vol EJMM29 (4) ◽  
pp. 135-141
Author(s):  
Nouran E. Samra ◽  
Shahira El-Etreby ◽  
Rasha H. El-Mahdy ◽  
Samah S. El-Kazzaz ◽  
Nariman M. El-Nashar
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune Response ◽  
Nuclear Dna ◽  
Inflammatory Responses ◽  
High Mobility ◽  
Dna Binding Protein ◽  
High Mobility Group ◽  
Over Expression ◽  
Different Types

Hepatocellular carcinoma "HCC" is a leading cause of cancer mortality worldwide. High-mobility group box 1 "HMGB1" is a nuclear DNA-binding protein which involved in DNA stability, programmed cell death, immune response and inflammatory responses in HCV and HCC. Its over expression was revealed in HCC and different types of human cancers.

Fibrolamellar Carcinoma With Predominantly Pseudoglandular Architecture: A Potential Diagnostic Pitfall

2020 ◽  
pp. 106689692093334
Author(s):  
Mariëtte du Toit ◽  
Alessandro Pietro Aldera
Keyword(s):  
Hepatocellular Carcinoma ◽  
Differential Diagnosis ◽  
Intrahepatic Cholangiocarcinoma ◽  
Systematic Approach ◽  
Metastatic Adenocarcinoma ◽  
Liver Mass ◽  
Diagnostic Pitfall ◽  
Fibrolamellar Carcinoma ◽  
Clinical Differential Diagnosis ◽  
Mass Lesions

Biopsies of liver mass lesions are encountered frequently in general surgical pathology practice. The clinical differential diagnosis is typically hepatocellular carcinoma (HCC) versus metastatic adenocarcinoma. There are a variety of HCC variants that show a range of morphological appearances. The presence of malignant glands in the liver prompts the pathologist to consider adenocarcinoma, either metastatic or primary intrahepatic cholangiocarcinoma. It is important to remember that some variant patterns of HCC can show pseudoglandular growth. In this article, we present a case of fibrolamellar carcinoma that showed predominantly pseudoglandular growth to highlight the importance of a systematic approach and the routine use of a panel of immunohistochemical stains (HepPar1, CK7, and CD68).

miR-320a regulates high mobility group box 1 expression and inhibits invasion and metastasis in hepatocellular carcinoma

2017 ◽  
Vol 37 (9) ◽  
pp. 1354-1364 ◽  
Author(s):  
Guixiang Lv ◽  
Mingjuan Wu ◽  
Meijie Wang ◽  
Xiaochen Jiang ◽  
Jingli Du ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
High Mobility ◽  
High Mobility Group ◽  
Invasion And Metastasis

scholarly journals Postoperative changes in high mobility group box 1 levels after colorectal cancer surgery

2016 ◽  
Vol 45 (6) ◽  
pp. 1651-1657 ◽  
Author(s):  
Masaaki Satoh ◽  
Kazuhiko Kotani ◽  
Shingo Yamada ◽  
Koji Koinuma ◽  
Hisanaga Horie ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
High Mobility ◽  
High Mobility Group ◽  
Colorectal Cancer Surgery ◽  
Reactive Protein ◽  
Amyloid A ◽  
Postoperative Changes ◽  
Potential Marker ◽  
Protein Serum ◽  
Potential Use

Objective To investigate the potential use of high mobility group box 1 (HMGB1) as a marker for the surgical course following surgery for colorectal cancer (CRC). Methods Patients with advanced CRC undergoing open colorectal surgery who did not develop postsurgical complications were enrolled in the study. Blood samples were taken preoperatively and at 1 day, 1 week and 3 weeks after surgery for the measurement of the white blood cell count, serum C-reactive protein, serum amyloid A and HMGB1. Results Data from 21 patients were analysed. HMGB1 levels changed significantly during the surgical course, increasing from a preoperative median of 6.8 ng/ml to 12.1 ng/ml at 1 day postoperatively, and then decreasing to 8.1 ng/ml at 1 week postoperatively and 4.0 ng/ml at 3 weeks postoperatively. These changes were similar to but were not completely correlated with the changes seen in the other markers. Conclusion Serum HMGB1 may be a potential marker to monitor the surgical course in patients undergoing surgery for CRC, although further studies are warranted before it can be introduced into routine clinical practice.

Sign in / Sign up

Export Citation Format

Share Document